Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.52 |
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.52 |
| ▸ | KMO | O15229 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937818 | 0.87 | KMO (0.68) | CYP1A2CYP3A4CYP2D6CYP2C19TSHR | |
| Hydrochloric Acid SCHEMBL28789722 | 0.85 | KMO (0.50) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1938479 | 0.84 | KMO (0.72) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1938372 | 0.84 | KMO (0.68) | SMN1; SMN2MAPTTP53HSD17B10KMO | |
| SCHEMBL1938969 | 0.83 | KMO (0.70) | KMO | |
| SCHEMBL1938336 | 0.83 | KMO (0.70) | KMO | |
| SCHEMBL30459427 | 0.83 | KMO (0.70) | KMO | |
| SCHEMBL1939837 | 0.81 | KMO (0.74) | SMN1; SMN2MAPTCYP1A2CYP2C19KMO | |
| SCHEMBL19385078 | 0.80 | GRM5 (0.52) | SMN1; SMN2MAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25224968 | 0.79 | KMO (0.80) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | WITYAK JOHN (US) | 2013-12-12 | — | — | US | claimed |
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-07-28 | — | — | US | claimed |
| EP-2331095-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9145373-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| EP-2331095-B1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | WITYAK JOHN (US) | 2013-12-12 | — | — | US | disclosed |
| US-8536186-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| WO-2013033068-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | disclosed |
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-07-28 | — | — | US | disclosed |
| EP-2331095-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | SMN1; SMN2 1120/4885MAPT 934/4885CYP1A2 354/4885 |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | SMN1; SMN2 1221/4885MAPT 865/4885CYP1A2 308/4885 |
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | SMN1; SMN2 1120/4885MAPT 934/4885CYP1A2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.